Sinovac Biotech may start late-stage trials of its coronavirus vaccine in the Philippines as early as next month, its food and drug agency chief said on Thursday, after it hurdled the initial stage of the country's screening process.
Pfizer confirmed Friday it expects to seek emergency authorization of its experimental vaccine against Covid-19, if it is effective, in the third week of November.
To understand the vaccine's efficacy-that is, whether it can protect individuals from COVID-19-a certain number of COVID-19 cases in the phase 3 trial need to be counted before investigators can compare the effectiveness of the vaccine with placebo.
Pfizer's shares rose 2.6% in early trading, while BioNTech's U.S-listed shares were up 2.8%.
Russian Federation has also promoted its Sputnik V vaccine overseas, despite concerns about its effectiveness and safety.
Despite President Donald Trump's repeated promises of a vaccine before Election Day, scientists had been cautioning that it's unlikely data showing a leading shot actually works would come until November or December.
Trump's hopes had been bolstered by Pfizer executives, who have said that they could have clinical trial results sometime in October.
That October timeline sounded even more aggressive when Moderna CEO Stephane Bancel, known for touting ambitious goals, said his company's shot, which was the first in the U.S.to move into clinical testing, likely wouldn't have data until November.
The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of Biological Products, a subsidiary of China National Biotec Group (CNBG).
"The Novosibirsk-based Vektor Centre has registered a second coronavirus vaccine, EpiVacCorona", Russian President Vladimir Putin said. This would allow the companies to file for an emergency use authorization. It has said that it may have interim data on its 30,000-person trial as soon as November.
A fourth vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June. They aim to be in a position to deliver tens of millions of doses to the USA by the end of the year.